Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.30 +3.8%	$16.16	$9.57 ▼ $29.86	$2.43B	0.93	1.56 million shs	1.25 million shs
GMTX Gemini Therapeutics	$56.27 -2.5%	$50.50	$1.16 ▼ $14.10	$2.44B	-0.12	189,291 shs	205,018 shs
IBRX ImmunityBio	$2.75 +0.4%	$2.76	$1.83 ▼ $7.48	$2.42B	0.08	6.30 million shs	6.40 million shs
MGTX MeiraGTx	$8.67 +1.2%	$6.33	$3.85 ▼ $8.98	$688.73M	1.24	405,548 shs	223,055 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.80%	-3.07%	+16.56%	+62.81%	-38.05%
GMTX Gemini Therapeutics	-2.55%	+6.23%	+4.77%	+37.24%	+14.30%
IBRX ImmunityBio	+0.36%	-1.43%	-12.14%	+11.34%	-57.03%
MGTX MeiraGTx	+1.17%	+3.58%	+30.97%	+60.26%	+78.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.7496 of 5 stars	3.4	2.0	0.0	3.4	3.1	1.7	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	2.1885 of 5 stars	3.6	1.0	0.0	0.0	2.5	1.7	0.6
MGTX MeiraGTx	4.2634 of 5 stars	3.5	1.0	0.0	4.8	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	138.88% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IBRX ImmunityBio	3.20	Buy	$12.25	345.45% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	176.82% Upside

Current Analyst Ratings Breakdown

Latest MGTX, IBRX, GMTX, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/12/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	711.90	N/A	N/A	$1.54 per share	11.88
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IBRX ImmunityBio	$31.22M	77.74	N/A	N/A	($0.57) per share	-4.82
MGTX MeiraGTx	$33.28M	20.94	N/A	N/A	$0.87 per share	9.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	20.73	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	22.82	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)

Latest MGTX, IBRX, GMTX, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	IBRX ImmunityBio	-$0.10	N/A	N/A	N/A	$21.95 million	N/A
8/11/2025	Q2 2025	MGTX MeiraGTx	-$0.52	N/A	N/A	N/A	$8.00 million	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
GMTX Gemini Therapeutics	N/A	71.49	71.49
IBRX ImmunityBio	N/A	2.22	2.05
MGTX MeiraGTx	2.34	1.53	1.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
GMTX Gemini Therapeutics	75.42%
IBRX ImmunityBio	8.58%
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
GMTX Gemini Therapeutics	12.90%
IBRX ImmunityBio	76.79%
MGTX MeiraGTx	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable

MGTX, IBRX, GMTX, and ARWR Headlines

Recent News About These Companies

MeiraGTx (NASDAQ:MGTX) Hits New 12-Month High - Here's What Happened

July 16 at 6:20 AM | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Down - What's Next?

July 11, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Sets New 1-Year High - Here's Why

July 10, 2025 | marketbeat.com

MeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past week

July 9, 2025 | finance.yahoo.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) CEO Alexandria Forbes Sells 47,500 Shares

July 8, 2025 | marketbeat.com

Insider Sell Alert: Alexandria Forbes Sells 47,500 Shares of MeiraGTx Holdings PLC

July 8, 2025 | gurufocus.com

MeiraGTx (NASDAQ:MGTX) Rating Increased to Hold at Wall Street Zen

July 5, 2025 | marketbeat.com

MeiraGTx Holdings PLC News (MGTX) - Investing.com

July 3, 2025 | investing.com

MeiraGTx Holdings plc (MGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

MeiraGTx (NASDAQ:MGTX) Stock Price Up 7.8% - Here's Why

July 2, 2025 | marketbeat.com

42,115 Shares in MeiraGTx Holdings PLC (NASDAQ:MGTX) Purchased by Acuitas Investments LLC

July 2, 2025 | marketbeat.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) Shares Acquired by Janney Montgomery Scott LLC

July 1, 2025 | marketbeat.com

3 Promising Genomics Stocks to Keep an Eye On in 2025

June 27, 2025 | zacks.com

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025 | globenewswire.com

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025 | globenewswire.com

FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment

May 10, 2025 | investing.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 9, 2025 | finance.yahoo.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

May 9, 2025 | globenewswire.com

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

April 29, 2025 | globenewswire.com

Richard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

April 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX, IBRX, GMTX, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.30 +0.67 (+3.80%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$18.56 +0.26 (+1.42%)

As of 07:06 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Gemini Therapeutics NASDAQ:GMTX

$56.27 -1.47 (-2.55%)

As of 07/15/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunityBio NASDAQ:IBRX

$2.75 +0.01 (+0.36%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.76 +0.02 (+0.55%)

As of 07:11 AM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

MeiraGTx NASDAQ:MGTX

$8.67 +0.10 (+1.17%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$8.68 +0.01 (+0.12%)

As of 07:00 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time